Cargando…
An Open‐Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM‐080301 in Subjects with Advanced Hepatocellular Carcinoma
LESSONS LEARNED. TKM‐080301 showed a favorable toxicity profile at the studied dose. TKM‐080301 targeting PLK1 through small interfering RNA mechanism did not demonstrate improved overall survival in patients with advanced hepatocellular carcinoma compared with historical control. Preliminary antitu...
Autores principales: | El Dika, Imane, Lim, Ho Yeong, Yong, Wei Peng, Lin, Chia‐Chi, Yoon, Jung‐Hwan, Modiano, Manuel, Freilich, Bradley, Choi, Hye Jin, Chao, Tsu‐Yi, Kelley, Robin K., Brown, Joanne, Knox, Jennifer, Ryoo, Baek‐Yeol, Yau, Thomas, Abou‐Alfa, Ghassan K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656521/ https://www.ncbi.nlm.nih.gov/pubmed/30598500 http://dx.doi.org/10.1634/theoncologist.2018-0838 |
Ejemplares similares
-
A Phase Ib, Open‐Label Study of Dalantercept, an Activin Receptor‐Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma
por: Abou‐Alfa, Ghassan K., et al.
Publicado: (2018) -
Phase II Study of First‐Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
por: Abou‐Alfa, Ghassan K., et al.
Publicado: (2017) -
Phase I Dose‐Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors
por: Cao, Junning, et al.
Publicado: (2017) -
Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH)
por: Ostwal, Vikas, et al.
Publicado: (2022) -
A Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric Cancer
por: Ryu, Min‐Hee, et al.
Publicado: (2017)